$VKTx VK2735 stacks up very well vs. all competitors 💥💥💥

ORCL Stock Slides To Early August Levels – $165B New Mexico Project In Focus After Company Reportedly Cites ‘Force Majeure’ $ORCL stocktwits.com/news-articles…

ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20% $ACAD stocktwits.com/news-articles…

$QURE the pullback from $50s provides a very interesting risk/reward for this Huntingtons Disease company. The 4 year data has been submitted already to the FDA ad is likely to show continued benefit in this dreadful, killing disease. Worth kicking the tires.

$AMLX double bottom breakdown — watch out below💥

barrons.com/articles/moderna… $MRNA

$VKTK are you naive or new to how secondaries are priced? Price it in the hole, put it with your favorite accounts and move on. Collect $$ put it in the bank.

$VKTX this deal is done. With over 55 million shares traded in two days — there is major interest from institutional investors in this company and their obesity position. Hiring both $JPM and $Ms shows that these major league firms were pitching hard for the business. Plus both will be more than happy to provide significant guidance should the phone ring from BigBioPharma— they both are experts in the M&A arena. Even though this is a small cap gem $VKTK has elevated their game big time on the maintenance data and made institutional investors real believers of what potential impact VK2735 could have in the LARGEST PHARMACEUTICAL MARKET in the world — $150 BILLION DiaBesity market. This is not a retail bulletin board company — this $4+ billion market cap play provides real upside going forward — and it is sizable💥💥💥

$VKTX I also like that $JPM and $MS are advising and running the books on the pending offering. It is helpful for CEO BL having these heavyweights on the payroll —especially as the inevitable calls come in from BigBioPharma with their indications of interest. If you want to play in the major leagues you have to pay up for talent💥💥💥

$VKTX the offering will be put to bed in a nanosecond. My guess is that this will be the last offering for quite a while and should hold them though ‘27. This small cap gem at less than $5 billion market cap continues to build out its space in the $150 billion obesity space & provides an attractive risk/reward profile at these levels.💥💥💥

$VKTX today’s action shows that there is plenty of firepower on the sidelines looking to get long $VKTX and take it higher — as the short term squeeze continues. Look for a new 52 week high perhaps today. The maintenance data is virtually impossible to ignore. For those in BigBioPharma not currently positioned in the $150 billion obesity space — it’s about time to engage with Viking.

fiercepharma.com/pharma/akes… $SMMT

fiercebiotech.com/biotech/mo…. $MRNA

MARTY ZWEIG — one of the true wizards & tacticians on Wall Street. You may be gone but your memory lives on💥💥💥💥

Viking shares surge on updated obesity drug data biopharmadive.com/news/vikin… via @BioPharmaDive. $VKTX

$VKTX hard to know what the short sellers were “thinking “ on this one. The commentary/ body language of management at recent HC conferences showed confidence in the pending maintenance data. Today’s monstrous volume shows that many have started to throw in the towel on this one and cover. The data also strengthens the institutional interest in this small cap gem as they get ready to carve out a nice piece of this $150+ obesity market. Does BigBioPharma finally start negotiating?🚀🚀🚀

$VKTX Truist $83 pt Truist analyst Gregory Renza says Viking Therapeutics' VK2735 obesity data this morning represents a "best-case scenario." Induction came in at 17.8% on 17.5 mg, with the exploratory continued-weekly cohort running to 21.7% by week 33 and still showing no plateau, the analyst tells investors in a research note. Truist says the readout "clears our bar, drawing a healthy balance of inbounds with the data a point of interest among a dense obesity landscape." VK2735's tolerability "came in clean," which "de-risks the step-down construct," the firm adds. It maintains a Buy rating on Viking Therapeutics with an $83 price target. The stock in morning trading is up 22% to $36.86.

$VKTX | B.Riley 𝗿𝗲𝗶𝘁𝗲𝗿𝗮𝘁𝗲𝘀 𝗕𝘂𝘆 on 𝗩𝗶𝗸𝗶𝗻𝗴 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, PT $𝟴𝟱, 'We are aggressive buyers of Viking Therapeutics' Analyst sees VK2735 maintenance data supporting less-frequent dosing, continued weight loss, and improved tolerability.

barrons.com/articles/viking-… $VKTX

cnbc.com/2026/09/22/novo-nor… $NVO